Bimatoprost 0.03% is a prostaglandin approved for the reduction of elevated IOP in patients with open angle glaucoma or ocular hypertension. Vistitan™ is currently the only marketed version of 0.03% bimatoprost ophthalmic solution for this indication in Canada and demonstrates that best ratio of safety to efficacy for this strength of the molecule. Aequus began Canadian promotional activities on behalf of its partner, for Vistitan™ in May 2016.
Aequus began promotional activities on Tacrolimus IR in December 2015. It was and remains the only lower cost alternative to the brand Prograf® currently marketed in Canada. Tacrolimus IR is indicated for the treatment and prevention of acute rejection following solid organ transplantation (liver, kidney and heart). Tacrolimus is part of a patient's immunosuppressive therapy prescribed chronically in their lifelong management to prevent graft rejection.
Contains lubricating eye drops intended for use in the relief of discomfort that arises from dry eye sensations, including dryness, soreness, feelings of grit, and irritation. They are ideal for sensitive eyes and provide intensive, durable lubrication.
Contains lubricating eye drops intended for use in the relief of discomfort that arises from dry eye sensations, including dryness, soreness, feelings of grit, and irritation. They are ideal for sensitive eyes and intensive dry eye symptoms.
Under the distribution agreement, Aequus will receive the Canadian commercial rights to 10 unique products of SCOPE’s portfolio of over-the-counter ophthalmology products including the OPTASE® range of preservative free dry eye products.
Preservative-free Bimatoprost 0.03%, ophthalmic solution.
Bimatoprost 0.03% is a prostaglandin approved for the reduction of elevated IOP in patients with open angle glaucoma or ocular hypertension. ZIMED™ PF is the first available multi-dose, preservative free, bimatoprost containing product in Canada. The anticipated timing for approval is December 2022.
REV-0100 is in preclinical development as a treatment for Stargardt disease. It was awarded both Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) designation by the US Food and Drug Administration. REV-0100 works by reducing levels of a toxic lipid called lipid bisretinoid, which accumulates within the retina in material called lipofuscin.
Aequus has entered into a partnership with ReVision on the development program and holds the exclusive right to negotiate North American commercial rights.
Has been involved in the Life Sciences industry for the past 19 years.
Currently the Founder and President of Northview Ventures, an organization which invests in and provides strategic advisory services to a number of technology companies.
President and CEO of Cardiome Pharma, a NASDAQ listed drug development company that raised over $300 million from investors, and completed over $1 billion in licensing deals during his tenure. In 2010, Cardiome’s lead product, Brinavess, was approved and launched in Europe by Merck.
Investment banker with Cormark Securities, acting as Managing Director of Life Sciences.
Past Chair of LifeSciences BC, has served as a Director with Biotech Canada and currently sits as a Director on a number of public and private boards.
Past winner of Business in Vancouver’s Top 40 Under 40 Award.
Background of operational and leadership experience in ophthalmology, with two of the largest ophthalmology companies in Canada and globally.
Worked with Allergan Canada for over 23 years, in a variety of roles across sales, marketing and management. Hi Last role at Allergan was Vice President, Regional President and General Manager, Canada.
Lead role as President and General Manager at Alcon Canada, the country’s leading ophthalmic med-device organization.
Principal at Fehr & Associates.
Served as CFO of Carrus Capital Corporation (formerly BioWest Therapeutic Inc.), Global Minerals Ltd., and other companies listed on the TSX.
Has led a number of companies through significant change and corporate milestones such as public listing applications, mergers and acquisitions, as well as strategic planning and execution.
Treasurer and a Director for the Boys and Girls Clubs of South Coast BC since 2013.
Joined the Aequus team in August of 2020 in the role of Chief Commercial Officer.
Close to 20 years of senior management positions in North American eye care industry.
In-depth knowledge of Canadian Optometry, direct to consumer marketing, online technology, and medical devices, brings important experience to accelerate growth for Aequus’ expanding portfolio of products.
Past CEO of Eye Recommend, one of Canada’s largest cooperatives of optometrists.
Held senior leadership positions at Allergan, Nikon Optical Canada, and Digital ECP.
Over ten years of progressive experience in the Pharmaceutical, Biotech, and Medical Device industry.
Co-Founder and Senior Partner of Northview Ventures, an entity which invests in and provides strategic advisory services to a number of life sciences companies.
Part of the founding group of Aequus Pharmaceuticals and previously held the title of VP of Corporate Development.
Served as the Corporate and External Affairs Analyst for Cardiome Pharma, where she was responsible for strategic planning and value analysis of internal R&D.
5 years with Bayer HealthCare, where she was responsible for the commercial success and business development of a portfolio of products within several key therapeutic areas.
Over 20 years finance and accounting experience in public practice and in public and private companies, most recently focused in the medical device sector.
Financial leadership roles with large automotive and telecom firms in which he developed deep expertise in the development and management of sophisticated financial systems.
Chief Financial Officer at Neovasc Inc. and was instrumental in the initial and ongoing development of Neovasc as a publicly traded company.
Received his designation as a Chartered Accountant from the Institute of Chartered Accountants of England and Wales and articled with KPMG before moving to Canada from England in 1998.
Honors degree in Economics from Swansea University and a post graduate diploma from Keble College, Oxford.
Marc Lustig joined the Aequus team in February of 2021 as a Director. Marc Lustig holds MSc and MBA degrees from McGill University.
He began his professional career in the pharmaceutical industry at Merck & Co. In 2000, he started his capital markets career in institutional equity research in the Life Sciences sector at Orion Securities. For the next 14 years, Mr. Lustig worked at GMP Securities L.P. and as Head of Capital Markets at Dundee Capital Markets before becoming a Principal at KES7 Capital.
In 2015 Mr. Lustig founded CannaRoyalty Corp. (Origin House). Origin House was sold to Cresco Labs in January 2020. Mr. Lustig is currently a Director of Cresco Labs and Pharmacielo Ltd. He is also Chairman of both Trichome Financial Corp. and IMC Cannabis.
The Annual General Meeting of shareholders of Aequus Pharmaceuticals Inc. will be held at the offices of Blake, Cassels, & Graydon LLP.
Address: 595 Burrard Street, Suite 2600, Vancouver, British Columbia, V7X 1L3
Date: August 4, 2022
Time: 10:00am (PDT)